Longevity News: FDA Officials Put Aging on the Agenda

ASLF Foundation Capsules: https://aslf-formulas.com/products/foundation-capsules Get them on Amazon: https://tinyurl.com/ASLFcapsules A COMPLETE LONGEVITY STACK IN ONE CAPSULE Instead of single-ingredient supplements, this stack works across multiple aging pathways at once to support energy, resilience, and long-term health. THIS WEEK IN LONGEVITY: A small randomized, double-blind trial tested the two-drug senolytic combo dasatinib plus quercetin in 31 people with MASH, a fatty liver disease. Liver scarring improved in 47% on the drugs versus 7% on placebo (Nature Metabolism, Oct 2026). The same combo missed its main bone goal in a 2024 trial, so this time the main goal was met, on liver biopsies. Side effects were more common but short-lived, and a bigger trial is needed to confirm. Also this week: - FDA officials said at the ARDD 2026 aging-research conference at Harvard that aging and longevity will be one topic in a planned FDA document on regulatory science priorities. No timeline, and no aging approval promised. - On Sep 27, Dubai approved the strategy and operating budget for the new Dubai Longevity Authority, which Dubai calls the world's first regulator dedicated to longevity. The budget wasn't disclosed. This is informational only and not medical advice. Always talk to your doctor before making changes to your health routine. SOURCES: Story 1, FDA: https://longevity.technology/news/fda-puts-aging-on-its-regulatory-science-agenda/ https://longevity.technology/news/ardd-2026-opens-at-harvard-with-a-call-for-rigor/ https://www.eurekalert.org/news-releases/1144599 Story 2, Dubai Longevity Authority: https://www.wam.ae/en/article/c2ghqfd-hamdan-bin-mohammed-approves-dubai-longevity Story 3, senolytics: New liver trial (Nature Metabolism, Oct 1): https://www.nature.com/articles/s42255-026-01643-4 Trial registration: https://clinicaltrials.gov/study/NCT05506488 Earlier 2024 bone trial (Nature Medicine): https://www.nature.com/articles/s41591-024-03096-2 One note: the FDA story comes from a trade outlet's report from the conference. There's no official FDA document yet.